Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms
- 1 December 2011
- journal article
- review article
- Published by Informa UK Limited in Expert Review of Hematology
- Vol. 4 (6), 619-625
- https://doi.org/10.1586/ehm.11.62
Abstract
Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases. However, the true incidence and mechanisms are not fully understood. LON has been reported in 5-27% of rituximab-treated lymphoma patients. Similar figures apply for autoimmune patients but they appear to have more infections during the neutropenic period. Recent reports imply that host factors may play an intriguing role for development of LON, for example, polymorphisms in FCGR3. Pronounced B-lymphocyte depletion and lower serum IgM, as reported in LON patients during the period of neutropenia compared with matched controls, may play a role for understanding the mechanisms and risk stratification for emergence of LON.Keywords
This publication has 45 references indexed in Scilit:
- Rituximab: Mechanism of ActionSeminars in Hematology, 2010
- The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseasesBritish Journal of Haematology, 2010
- The late adverse events of rituximab therapy – rare but there!Leukemia & Lymphoma, 2009
- Rituximab therapy in malignant lymphomaOncogene, 2007
- A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution studyAnnals Of Oncology, 2006
- Late-Onset Neutropenia in Patients Treated with Rituximab for Non-Hodgkin's LymphomaInternational Journal of Hematology, 2006
- Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritisArthritis & Rheumatism, 2006
- Delayed-onset peripheral blood cytopenia after rituximab: Frequency and risk factor assessment in a consecutive series of 77 treatmentsLeukemia & Lymphoma, 2006
- B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasisBlood, 2005
- Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphomaBone Marrow Transplantation, 2004